Field efficacy and safety of protamine zinc recombinant human insulin in 276 dogs with diabetes mellitus
| Autor: | J. Li, K. Christiansen, C.R. Ward, W.L. Bryson, K.A. Jerrentrup, C. Kroh |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Glycosuria
Blood Glucose medicine.medical_specialty medicine.medical_treatment law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Endocrinology Dogs Food Animals Polyuria law Weight loss Diabetes mellitus Internal medicine medicine Diabetes Mellitus Animals Humans Hypoglycemic Agents Insulin Dog Diseases Prospective Studies Protamines 030219 obstetrics & reproductive medicine business.industry 0402 animal and dairy science 04 agricultural and veterinary sciences medicine.disease 040201 dairy & animal science Fructosamine chemistry Recombinant DNA Animal Science and Zoology medicine.symptom business Polydipsia |
| Zdroj: | Domestic animal endocrinology. 75 |
| ISSN: | 1879-0054 |
| Popis: | Twice-daily (BID) insulin injections are a major deterrence to owners treating dogs with diabetes mellitus (DM). The hypothesis for this study was that Protamine Zinc Recombinant Human Insulin (PZIR) is safe and efficacious as a once-daily (SID) treatment for canine DM. This was a prospective, baseline-controlled, multi-center study over 182 ± 5 d. Two hundred seventy-six client-owned dogs with naturally occurring DM (naïve or pre-treated with insulin) were enrolled in the study. Enrollment was based upon demonstration of hyperglycemia, glycosuria, and ≥1 diabetic clinical sign (polyuria (PU), polydipsia (PD), or weight loss). Insulin treatment was initiated at 0.5-1.0 IU/kg SID. An improvement in at least one lab parameter related to DM (mean BG, min BG, Fructosamine) and one clinical parameter (PU/PD, body weight) was achieved in 72% of dogs (80% of naive, 62% of pre-treated). Dogs treated SID and BID showed improvement in 71% and 74% of cases, respectively. In naïve dogs, mean and minimum BG and fructosamine were significantly decreased (P0.05) by d 7 and 21, respectively, and in pre-treated dogs by d 63. By d 84, PU/PD improved in 90% and 88% of dogs, respectively, and the mean successful insulin dose was 1.4 IU/kg/d. Safety parameters were measured in 276 dogs for up to 182 d; clinical hypoglycemia occurred in 8.9% of dogs. We conclude that PZIR safely and effectively improved glycemic parameters and clinical signs in naïve and pre-treated diabetic dogs. The significant percentage of dogs on SID treatment with improvement in hyperglycemia and clinical signs confirms the prolonged action of PZIR in many dogs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect